Kissei Pharmaceutical And Wakamoto Pharmaceutical Co-Promote Salagen
This article was originally published in PharmAsia News
Kissei Pharmaceutical and Wakamoto Pharmaecutical signed an agreement May 2 to co-promote Kissei's Salagen (pilocarpine), a drug used to treat dryness of the mouth and throat that may occur after radiation treatment for cancer of the head and neck, and to patients with Sjogren's syndrome. Kissei obtained the drug's exclusive development and marketing right in Japan from MGI Pharma, a subsidiary of Eisai. According to the agreement, Kissei and Wakamoto will promote the drug to assigned medical facilities, but Kissei will continue to solely handle manufacturing, marketing and distribution. (Click here for more - Japanese language
You may also be interested in...
Companies including Dr Reddy’s will consider investing in new API units if the Indian government tweaks its incentive scheme to permit exports of surplus production. Other suggested changes to the $1.3bn stimulus, aimed at enhancing the country's medicines security, include extending incentives to brownfield expansions and removing restrictions on a change in product mix.
The Global Generics & Biosimilars Awards 2020 will take place on 3 November as a digital event, with a newly-extended entry deadline date of 14 August.
Developed by Japan’s national research institute, the supercomputer has been tasked with characterizing the SARS-CoV-2 virus, identifying therapeutic molecules, modeling infection spread and socio-economic impact.